Assessing Turoctocog Alfa Treatment in Iraqi Patients with Haemophilia A
Descriptive Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients - An Observational Retrospective Study
This study looks at how well turoctocog alfa works for Iraqi men with haemophilia A who are switching from their current treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 900 (estimated) |
| Sex | Male |
| Sponsor | Novo Nordisk A/S Industry-sponsored |
| Locations | 7 sites (Baghdad and 6 other locations) |
| Trial ID | NCT06574984 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the use of turoctocog alfa in the management of haemophilia A among Iraqi patients. It will collect data from existing medical records to establish a baseline for treatment practices without altering current clinical management. Participants will include both pediatric and adult males who have previously received FVIII replacement therapy. The study will focus on patients transitioning to turoctocog alfa, gathering information during their routine visits.
Who should consider this trial
Good fit: Ideal candidates include male patients of all ages with haemophilia A who have previously been treated with FVIII replacement therapy.
Not a fit: Patients with other coagulation disorders or those with FVIII inhibitors will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of turoctocog alfa's effectiveness and safety in real-world settings for haemophilia A patients.
How similar studies have performed: While this study is observational and focuses on existing treatment practices, similar studies have shown that real-world data can provide valuable insights into treatment effectiveness.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Paediatric and adult male patients * On-demand and prophylactic patients with haemophilia A (any severity) * Only previously treated patients (previous FVIII replacement therapy) will be included in the study Exclusion Criteria: * Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease * Patients with documented presence of any FVIII inhibitor
Where this trial is running
Baghdad and 6 other locations
- National centre for Hamophilia — Baghdad, Iraq (Enrolling_by_invitation)
- Novo Nordisk Investigational Site — Baghdad, Iraq (Recruiting)
- Basrah Haemoplhilia centre — Basra, Iraq (Not_yet_recruiting)
- Hilla Haemophilia centre — Hillah, Iraq (Enrolling_by_invitation)
- Karbala Haemophilia centre — Karbala, Iraq (Enrolling_by_invitation)
- Kirkuk Centre for Cancer and Blood Disorders — Kirkuk, Iraq (Enrolling_by_invitation)
- Najaf Haemophilia Centre — Najaf, Iraq (Enrolling_by_invitation)
Study contacts
- Study coordinator: Novo Nordisk
- Email: clinicaltrials@novonordisk.com
- Phone: (+1) 866-867-7178
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.